Adrenalone

Adrenalone

SCHEMBL123124

CNCC(=O)c1ccc(O)c(O)c1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPG P10696 9/20 0.55
ALPL P05186 8/20 0.55
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA7 P43166 3/20 0.53
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 3/20 0.53
XDH P47989 1/20 0.53
KDM4E B2RXH2 2/20 0.50
GAA P10253 2/20 0.50
POLB P06746 2/20 0.50
MAPT P10636 1/20 0.50
CA4 P22748 1/20 0.50
CA6 P23280 1/20 0.50
PTGS2 P35354 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
PLAA Q9Y263 6/20 0.49
DBH P09172 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adrenalone SCHEMBL29550997 1.00 ALPG (0.55) ALPGALPLCA12CA1CA2
Adrenalone SCHEMBL6662605 0.98 ALPG (0.54) ALPGALPLCA12CA1CA2
Adrenalone SCHEMBL28668200 0.96 ALPG (0.52) ALPGALPLCA12CA1CA2
SCHEMBL6046293 0.81 ALPG (0.52) ALPGALPLCA12CA1CA2
SCHEMBL7441728 0.81 ALPG (0.52) ALPGALPLCA12CA1CA2
SCHEMBL20310071 0.81 ALPG (0.40) ALPGALPLCA12CA1CA2
SCHEMBL14646958 0.81 ALPG (0.51) ALPGALPLCA12CA1CA2
SCHEMBL9768178 0.80 KDM4E (0.53) ALPGALPLCA12CA1CA2
SCHEMBL31419971 0.80 ALPG (0.51) ALPGALPLCA12CA1CA2
SCHEMBL29391092 0.80 KDM4E (0.53) ALPGALPLCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118255674-B Method for preparing isoprenaline hydrochloride 北京均大检测科技有限公司 2025-02-11 CN claimed
CN-119263998-A Production method of adrenalone hydrochloride capable of improving yield 蚌埠丰原涂山制药有限公司 2025-01-07 CN claimed
CN-116082173-B Preparation method of dopamine hydrochloride 武汉武药制药有限公司 2024-11-01 CN claimed
CN-118255674-A Method for preparing isoprenaline hydrochloride 北京均大检测科技有限公司 2024-06-28 CN claimed
CN-118225915-A Evaluation method and application of epinephrine injection 武汉久安药物研究院有限公司 2024-06-21 CN claimed
US-11903992-B2 Composition comprising lidocaine, l-carnosine and dexpanthenol CELLIX BIO PRIVATE LIMITED (IN) 2024-02-20 US claimed
CN-110184299-B Factor inducing reprogramming of cells and method for inducing reprogramming of cells using the same 中国科学院广州生物医药与健康研究院 2023-11-24 CN claimed
CN-113512521-B Additive of serum-free culture medium, serum-free culture medium and application thereof 江苏普瑞康生物医药科技有限公司 2023-06-23 CN claimed
CN-113583984-B Cytochrome P450 monooxygenase CYP109B2 and application thereof 湖北大学 2023-05-23 CN claimed
CN-115101204-A Model, equipment and storage medium for quantitatively evaluating depression risk based on blood biochemical indexes 中国科学院心理研究所 2022-09-23 CN claimed
WO-2003066029-A2 PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY PHARMACIA CORPORATION (US) 2003-08-14 WO claimed
WO-2003032969-A2 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2003-04-24 WO claimed
CN-1367698-A Administration of non-oral androgenic steroids to women WATSON PHARMACEUTICALS INC (US) 2002-09-04 CN claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
US-6218575-B1 ASYMMETRIC HYDROGENATION OF N-PROTECTED ADRENALONE USING DICHLOROBIS((CYCLOOCTA-1,5-DIENE) RHODIUM (I)) AND BIDENTATE PHOSPHINE LIGAND CATALYST SYSTEM; PRECIPITATION, DEBLOCKING BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-04-17 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5047592-A Selective hydrogenolysis process ETHYL CORPORATION (US) 1991-09-10 US claimed
US-4594356-A Topical administering an adrenalone derivative KEY PHARMACEUTICALS, INC. (US) 1986-06-10 US claimed
US-4313956-A Novel sypathomimetic amine prodrugs INTERX RESEARCH CORP. (US) 1982-02-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11903992-B2 Composition comprising lidocaine, l-carnosine and dexpanthenol VNN1, LPL, HMGB1 ALPG 3733/4885ALPL 2145/4885CA12 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.